Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

This was the stock's third consecutive day of losses.

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of ...

This was the stock's second consecutive day of losses.

Health care stocks trended downward for most of 2024, significantly underperforming broader stock indexes. Over the past year, the S&P 500 Health Care index rose by only 0.

BofA Securities has recently resumed AbbVie Inc (ABBV) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on December 5, 2024, Daiwa Securities had reduced the ...

CWA Asset Management Group LLC cut its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 13.1% in the 4th quarter, ...